Key Takeaways
- India powers through, US stabilizes: India business grew 16.7% YoY in Q4, driven by acute tailwinds and chronic outperformance, while US full-year sales declined 4% on double-digit price erosion, partially offset by record new launches.
- Margin reset underway: Raw material cost spikes and freight inflation will compress EBITDA margin by 150–175 bps in FY23, pulling it toward ~18%, with recovery contingent on input costs softening from FY24.
- Biosimilars bet is funded but distant: Enzene burned ~₹100 crores of EBITDA in FY22; management guides ~₹250 crores revenue next year, but the big regulated-market payoff is 3–4 years away, with US filing targeted for end-2024.
- Chronic portfolio ambition is concrete: Management aims to scale the chronic franchise to ₹1,000–2,000 crores in 3–4 years, anchored on Dapagliflozin/Sita combinations and a plan to double the prescriber base.
- What to watch next quarter: Whether Q1 FY23 gross margin absorbs the high-cost inventory as guided, the pace of US quarterly ramp toward the 10–12% full-year growth target, and any further softening in raw material prices.
India Business: The Growth Engine
- Broad-based therapy momentum: Acute therapies (anti-infective, vitamins/minerals/nutrients, pain, gastrointestinal) drove Q4, while the chronic portfolio grew at nearly 2x the market growth rate for the full year.
- Respiratory entry: The newly launched Pulmocare division saw an encouraging start, with growth higher than the therapy growth rate.
- Trade generics resilience: The trade generic business posted strong performance despite a high base; management believes the market has room for competitors because medicine reach in India is still only 40–45% of the population.
- Volume and price levers: India volume growth is 3–5%, with price increases contributing ~6–7% and new introductions ~3%, making price a big lever this year.
- Chronic productivity gap: Current chronic PCPM is ~₹3–3.25 lakhs, well below peers; management aims to double the prescriber base in 2–3 years to close that gap.
- MR footprint: The fieldforce is nearly saturated; only 200–300 strategic additions are planned over the next few years.
Sandeep Singh: "Price is a big lever this year, around 7%."
US Business: Price Erosion Easing, Launches Filling the Gap
- FY22 damage: Full-year US sales of $318 million, down 4% YoY, as lower-double-digit price erosion (~11–12%) completely offset the impact of new product launches, even though some launches had limited competition.
- Base business erosion: The base business degrew significantly from price erosion and, in some cases, loss of market share; new business contribution last year was one of the highest ever, which kept the overall decline to only a small degrowth.
- FY23 price outlook: Price erosion expected to moderate to higher single digits, down from ~11–12% in FY22.
- FY23 growth guidance: US revenue growth guided at 10–12% for FY23; management noted this represents only ~7% growth over FY21, since FY22 was a depressed base.
- Quarterly cadence: Q1 FY23 expected to show 10–12% YoY growth versus Q1 FY22; growth is not dependent on any single event or product and must be delivered fairly evenly during the year.
- Profitability undisclosed: Management declined to split profits by market but stated the US is well beyond breakeven and contributes more than 25% of revenues; segment margins are not disclosed.
Sandeep Singh: "The entire FY22 was depressed compared to FY21, so as you can see we have degrown by 5% in the current year, so if I am basically guiding them to 12% increase over FY22, in fact we are only guiding for 7% increase over FY21."
Margin Walk: The Raw Material Overhang
- Q4 gross margin hit: Gross margin was impacted by ~1.6–1.7% from enhanced material cost and an equivalent ~1.7% from US price erosion.
- FY22 gross margin: A positive 20 bps addition for the full year, helped by a product mix shift as India's revenue share rose from 65% to 70%; input cost increases did not have significant impact in FY22 itself.
- The inventory lag: Material prices started rising in October, peaked in November–December with scarcity concerns; the company accumulated higher-cost inventory that was partially consumed in Q4, but the major portion will hit in Q1 FY23 and possibly early Q2.
- FY23 gross margin guidance: Normal gross margins of 61–62% will compress to 59–60%, a 100–150 bps impact on a full-year basis, driven by high raw material cost.
- FY23 EBITDA margin: Estimated 150–175 bps hit for the full year, pulling EBITDA margin toward ~18% from 19.3% in FY22; stabilization expected in FY23, improvement from FY24 onwards if the inflationary environment eases.
- Freight costs: Sharp increases in both domestic and international freight rates will add pressure going forward.
- Operating leverage insufficient: Operating leverage will come in but will not offset all the price increases absorbed this year.
- Margin expansion ambition: Management acknowledged that adding even 50–100 bps to EBITDA margin is a tough task; cost optimization levers have been identified across manufacturing, R&D facilities, and distribution.
Rajesh Dubey: "So, one good thing now, this material prices, it has started showing softening trend and that good thing happening, but whatever material we have procured, ultimately we are going to consume it..."
Biosimilars (Enzene): Investment Phase, Distant Payoff
- FY22 performance: Enzene contributed negatively to EBITDA by around ₹100 crores; the year saw 3 product launches in India, onboarding of multiple companies for CDMO services, and several out-licensing agreements with leading international companies.
- FY23 revenue guide: ~₹250 crores in revenue expected next year.
- Investment to date: ~₹750 crores already invested, with an additional ~₹100 crores in R&D per year, a figure that can go up over the next couple of years.
- Regulated-market timeline: Global clinical trials have been initiated on selected products; US filing for Denosumab targeted around 2024 end; big growth from regulated markets (US, Europe) is still 3–4 years away.
- Out-licensing traction: Products have been out-licensed to European players who have provided good upfront payments.
Chronic Portfolio: The Next Leg
- Current scale and ambition: The chronic portfolio is not as big as acute but not small now; management targets around ₹1,000 to ₹2,000 crores in 3 to 4 years' time, anchored on Dapagliflozin, Sita, Dapa combinations that have worked around Rs. 300 to Rs. 500 crores in 2 to 3 years' time.
- Productivity unlock: Current chronic PCPM of ~₹3 lakhs is well below peers; the plan is to double the prescriber base in the next 2–3 years to drive productivity improvement.
- Growth trajectory: Chronic segment will continue to grow by good double-digit volume; overall domestic business growth is expected around 13%, with acute at 10–11% and chronic at ~20% (double the market growth rate).
- Market normalization: Both acute and chronic market growth are expected to return to near pre-COVID levels, around 10–11% each.
Yogesh Koushal: "Right now, we should be ... around ₹1,000 to ₹2,000 crores in 3 to 4 years' time."
Capital Allocation & Strategy: Conservative, Focused
- No large acquisitions: Management's conservative DNA is unchanged; India acquisition opportunities are expensive and often involve acquiring whole businesses with fieldforce and cultural complications, not just brands.
- Geographic focus unchanged: India, US, and key ROW markets remain the core; biosimilars is the only new frontier.
- CAPEX: No major CAPEX lined up.
- Tax rate: Expected between 11% to 14% for the next 2 years; facilities come out of 80-IE around FY26–27, at which point fresh guidance will be provided.
- Other international markets: Delivered robust 35% YoY growth for the full year, led by Australia and Chile, driven by new launches and lower price erosion than the US; double-digit growth expected to sustain.
- R&D spend: Guided at 5.5% to 6% of sales for FY23; ~90% is for the US, with biosimilars a part but not the large part.
Sandeep Singh: "We continue to be the same, DNA has not changed, we are conservative, we will do what know to do best and so no large acquisition plans Prakash bhai."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India revenue growth | Double-digit growth in FY23 | FY23 |
| India growth split | Price ~6–7%, new introductions ~3%, volume 3–5% | FY23 |
| US revenue growth | 10–12% YoY growth | FY23 |
| US price erosion | Higher single digits (vs ~11–12% in FY22) | FY23 |
| Other international markets growth | Double-digit growth sustained | FY23 |
| Gross margin | 59–60% (down from normal 61–62%), a 100–150 bps impact | FY23 |
| EBITDA margin | ~18% (down from 19.3% in FY22), a 150–175 bps hit | FY23 |
| Gross margin recovery | Back to 60–61% levels | FY24 onwards |
| EBITDA margin trajectory | 50–100 bps decline in FY23, then hopefully going up | FY23, then recovery |
| R&D spend | 5.5% to 6% of sales | FY23 |
| Biosimilars revenue | ~₹250 crores | FY23 |
| Biosimilars US filing (Denosumab) | Filing around end-2024 | End-2024 |
| Biosimilars regulated-market launch | Big growth when launched in US and Europe | 3–4 years away |
| Chronic portfolio scale | ₹1,000–2,000 crores | 3–4 years |
| Tax rate | 11% to 14% | Next 2 years (until ~FY26–27) |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue from operations | 13.3% YoY growth |
| India business revenue growth | 16.7% YoY |
| US business revenue growth | Almost flat YoY |
| Other international business revenue growth | 35.3% YoY |
| EBITDA margin | 13.6% |
| Full-year EBITDA margin | 19.3% |
| Full-year gross margin | 60.7%, positive 20 bps addition YoY |
| India business share of total sales | 70% for FY22, up from 65% in FY21 |
| US business full-year sales | $318 million, down 4% YoY |
| US price erosion, full-year | 11–12% (lower double digits) |
| US price erosion guidance for FY23 | Higher single digits |
| US revenue growth guidance for FY23 | 10–12% |
| ANDAs filed with US FDA during the year | 14 filed, 21 approvals received |
| Total ANDAs filed with US FDA | Over 160, nearly half yet to be commercialized |
| ANDAs currently selling in the US | About 85, roughly 15 yet to reach full potential |
| India branded business split | 85% acute, 15% chronic |
| Trade generic share of India business | 22% |
| India price increase expected for FY23 | 6–7% |
| India new introduction contribution expected | ~3% |
| India volume growth expected | 3–5% |
| India market share gain vs IPM | 0.3% increase |
| Total medical representative count | 10,000, split 17% chronic and rest acute |
| MR productivity, acute | ~₹6 lakhs PCPM |
| MR productivity, chronic | ₹3–3.25 lakhs PCPM |
| MR additions in Q4 FY22 | 500 people added |
| R&D spend as percentage of sales | ~6.4% in Q4; FY23 guidance 5.5–6% |
| R&D spend allocation to US | ~90% |
| Biosimilars revenue expectation for next year | ~₹250 crores |
| Biosimilars investment to date | ~₹750 crores |
| Biosimilars annual R&D investment going forward | ~₹100 crores per year |
| Enzene negative EBITDA contribution | ~₹100 crores last year |
| Tax rate guidance for next 2 years | 11–14% |
| FY23 EBITDA margin expectation | ~18%, reflecting 150–175 bps hit from input costs |
| FY23 gross margin expectation | 59–60%, down 100–150 bps from FY22 |
| Q4 gross margin impact from high raw material cost | 1.6–1.7% |
| Q4 gross margin impact from US price erosion | ~1.7% |
| US contribution to total revenue | More than 25% |
| Chronic portfolio size relative to acute | Around one third of acute |
| Domestic business growth expectation for FY23 | ~13% overall, acute 10–11%, chronic ~20% |